SAN.PA
Sanofi
ParisEUREQUITY
Healthcare
DELAYED
Last price
78.91
▲ 1.12 (1.44%)
MARKET · —
Price
Open
77.40
Prev close
77.79
Day high
79.01
Day low
77.19
Volume
1.47M
Market cap
$94.58B
P/E (TTM)
24.75
52W range
71.25 – 91.15
Trailing performance
Returnvs SPY
1W
+1.78%
+3.1%
1M
+1.24%
-2.5%
3M
+0.43%
-2.7%
6M
-2.25%
-13.3%
YTD
-5.96%
-18.2%
1Y
-9.82%
-29.8%
3Y
-21.11%
-95.3%
5Y
-4.09%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$94.58B
Enterprise value$112.16B
Revenue (TTM)$48.92B
Gross profit$35.93B
EBITDA$13.54B
Net income$3.94B
EPS (TTM)$3.19
Free cash flow$6.30B
Total cash$6.35B
Total debt$23.58B
Book value / share$57.77
Shares outstanding1.20B
Float1.08B
Short % of float—
Dividend yield5.22%
Beta (5Y)0.28
Valuation & profitability ratios
Trailing P/E24.75
Forward P/E8.71
PEG ratio29.79
Price / sales—
Price / book1.37
EV / revenue2.29
EV / EBITDA8.28
Gross margin73.45%
Operating margin21.03%
Profit margin8.09%
Return on equity5.71%
Return on assets5.09%
Debt / equity33.89
Current ratio0.99
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $43.63B | $41.08B | $43.07B | $43.00B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $7.81B | $5.74B | $5.40B | $6.72B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $7.81B | $5.74B | $5.40B | $6.72B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.90 | 2.09 | +10.0% |
| Mar 2026 | 1.80 | 1.88 | +4.5% |
| Dec 2025 | 1.47 | 1.53 | +4.4% |
| Sep 2025 | 2.70 | 2.91 | +7.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.89 | 9 | $13.17B | +5.9% |
| Next quarter | 1.76 | 9 | $12.49B | +10.5% |
| Current year | 8.59 | 20 | $47.59B | +9.1% |
| Next year | 9.07 | 20 | $50.70B | +6.5% |
Analyst targets & ownership
Mean target$94.28
High target$112.00
Low target$78.00
Implied upside19.48%
Analyst count23
ConsensusBUY
Strong buy / Buy2 / 10
Hold12
Sell / Strong sell0 / 0
Held by insiders10.31%
Held by institutions42.85%
Institutions holding854
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
123.56M
Total on file
Moving averages & technicals
SMA 10
76.43
+3.25% from price
SMA 20
76.12
+2.20% from price
SMA 50
75.68
+2.79% from price
SMA 100
76.65
+2.95% from price
SMA 200
79.15
-1.72% from price
EMA 12
76.63
+2.97% from price
EMA 26
76.22
+3.52% from price
EMA 50
76.14
+3.64% from price
RSI (14)
57.0
Neutral
MACD (12,26,9)
0.41
Hist 0.31
ATR (14)
1.39
1.79% of price
Realised vol 30D
32.2%
Annualised
Bollinger upper
79.78
20, 2σ
Bollinger lower
72.45
20, 2σ
50 / 200 cross
Death
75.68 vs 79.15
Trend bias
Below 200
-1.72%
Risk profile
Beta vs SPY
0.05
Less volatile than market
Correlation to SPY
0.03
Largely independent
Realised vol 30D
32.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-19.8%
Peak to trough
Max drawdown 5Y
-33.9%
Peak to trough
ATR 14
1.39
1.79% of price
Beta (reported)
0.28
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Dozens of civilians killed, kidnapped as jihadists clash in Nigeria
AFP · 12m ago
EOG Resources (EOG) Stock Still Looks A Bargain On Earnings Yet Fully Priced On Returns
Simply Wall St. · 14m ago
Artemis Gold (TSXV:ARTG) Stock Still Looks Reasonable Despite Its 7x Run
Simply Wall St. · 15m ago
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update
Simply Wall St. · 15m ago
Scholar Rock (SRRK) Stock Looks Stretched On Book Value But Strong On Returns
Simply Wall St. · 15m ago
Regions Financial (RF) Stock Could Trade At A 48% Discount On Earnings Power
Simply Wall St. · 15m ago
Tonies (DB:TNIE) On Half Year Results, Can The Bull Case Still Support Fair Value?
Simply Wall St. · 15m ago
Hut 8 (HUT) Gets Court Approved Notice For $2,350,000 Settlement
Simply Wall St. · 16m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.